List of Excipients in Branded Drug METFORMIN HYDROCHLORIDE EXTENDED-RELEASE 500MG

Generic Drugs Containing METFORMIN HYDROCHLORIDE EXTENDED-RELEASE 500MG

Company	Ingredient	NDC	Excipient
Calvin Scott & Co Inc	metformin hydrochloride	17224-311	CARBOXYMETHYLCELLULOSE SODIUM
Calvin Scott & Co Inc	metformin hydrochloride	17224-311	CELLULOSE, MICROCRYSTALLINE
Calvin Scott & Co Inc	metformin hydrochloride	17224-311	COPOVIDONE K25-31
Calvin Scott & Co Inc	metformin hydrochloride	17224-311	HYPROMELLOSE
Calvin Scott & Co Inc	metformin hydrochloride	17224-311	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in METFORMIN HYDROCHLORIDE EXTENDED-RELEASE 500MG?

# Of NDCs	Excipient
1	CARBOXYMETHYLCELLULOSE SODIUM
1	CELLULOSE, MICROCRYSTALLINE
1	COPOVIDONE K25-31
1	HYPROMELLOSE
1	MAGNESIUM STEARATE

Metformin Hydrochloride Extended-Release 500 mg: Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Metformin hydrochloride extended-release 500 mg is a mature, high-volume generic product with limited protection from core drug patents. Commercial differentiation depends on release-control performance, tablet size, gastrointestinal tolerability, manufacturability, nitrosamine control, and supply economics. The strongest excipient opportunity is a robust hydrophilic matrix platform using hypromellose or a polymer combination that delivers reliable 12- to 24-hour release across food conditions and manufacturing-scale variation.

What is the commercial status of metformin hydrochloride extended-release 500 mg?

Metformin hydrochloride extended-release tablets are approved in the United States as generic equivalents to Glucophage XR. The reference product was developed as a once-daily extended-release formulation for type 2 diabetes mellitus. The FDA approved Glucophage XR under NDA 021202 in 2000, and multiple abbreviated new drug applications now cover 500 mg, 750 mg, and 1,000 mg strengths.[1]

Commercial attribute	Assessment
Active ingredient	Metformin hydrochloride
Dosage form	Oral extended-release tablet
Common strength	500 mg
Reference product	Glucophage XR
Reference applicant	Bristol-Myers Squibb
FDA pathway for generics	ANDA, generally with bioequivalence to the reference product
Therapeutic area	Type 2 diabetes
Prescription status	Prescription drug
Generic competition	Extensive
Core patent barrier	Largely expired for the original extended-release platform
Main commercial barriers	Bioequivalence, tablet size, GI tolerability, manufacturing cost, supply reliability, nitrosamine control

Metformin remains a high-volume medicine because it is widely used as first-line pharmacotherapy for type 2 diabetes and is also used in combination regimens. The extended-release form has commercial value because it can improve dosing convenience and may reduce gastrointestinal intolerance compared with immediate-release metformin in some patients.[2]

The product is not a biologic and does not create biosimilar risk. Competitive pressure comes from generic manufacturers, authorized generics, contract manufacturers, and fixed-dose combination products.

What excipients are used in metformin extended-release tablets?

The main excipient function is to control water ingress, drug diffusion, polymer swelling, tablet erosion, and drug release over the intended dosing interval. A typical formulation may contain the following excipient categories:

Excipient category	Examples	Primary function
Hydrophilic matrix polymer	Hypromellose, polyethylene oxide, hydroxypropyl cellulose	Swelling, gel formation, diffusion control
Hydrophobic release modifier	Ethylcellulose, glyceryl behenate, stearic acid	Slower water penetration and drug diffusion
Binder	Povidone, copovidone, hydroxypropyl cellulose	Granule and tablet strength
Diluent	Microcrystalline cellulose, lactose, mannitol	Flow, compressibility, tablet mass adjustment
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection and tooling protection
Glidant	Colloidal silicon dioxide	Powder flow
Film coating	Hypromellose, polyethylene glycol, titanium dioxide, colorants	Identification, swallowing, moisture protection
Processing aid	Alcohol, purified water, granulation solvents	Wet or fluid-bed granulation

Metformin hydrochloride has a high dose-to-tablet-mass ratio. A 500 mg strength therefore places substantial pressure on excipient selection, granulation efficiency, tablet hardness, and tablet dimensions. A matrix system must maintain release control without producing an excessively large tablet.

Which excipient strategy is strongest for a 500 mg metformin extended-release tablet?

A hydrophilic matrix based on hypromellose is the most commercially established strategy. Hypromellose hydrates after ingestion, forms a gel layer, and controls release through a combination of diffusion and matrix erosion. The polymer grade, viscosity, particle size, concentration, and distribution within the granule can materially affect dissolution.

A practical development platform is:

1. Metformin hydrochloride as the high-load active.
2. Hypromellose as the principal matrix former.
3. Microcrystalline cellulose or another compressible diluent to improve tablet strength.
4. Povidone or copovidone to support granule integrity.
5. A low-level lubricant and glidant system selected to preserve dissolution performance.
6. A protective film coat with low moisture permeability.

The formulation should be designed around the target dissolution profile rather than excipient identity alone. Relevant critical quality attributes include:

• Assay and content uniformity.
• Tablet hardness and tensile strength.
• Friability.
• Water content.
• Drug release at multiple dissolution time points.
• Alcohol-induced dose-dumping resistance.
• Stability under accelerated and long-term conditions.
• Tablet dimensions and swallowability.
• Mechanical robustness during packaging and transport.

A single-polymer matrix is generally easier to scale and defend from a regulatory standpoint. A dual-polymer system can provide more release-control flexibility but may increase formulation complexity and create a larger design space for manufacturing variability.

When should a hydrophobic matrix be considered?

Hydrophobic excipients such as ethylcellulose or lipid-based materials can reduce water penetration and extend drug release. They may be useful where a hydrophilic matrix releases too quickly or where the target profile requires stronger resistance to agitation and food-related changes.

The tradeoff is greater process sensitivity. Hydrophobic systems can produce variable wetting, poor content uniformity, or inadequate release at later time points if the coating or matrix is over-engineered. They can also complicate scale-up and may require tighter control of granulation and lubrication.

For a 500 mg product, a hydrophilic matrix is generally the lower-risk starting point. A hydrophobic or dual-matrix design is more relevant as a second-generation platform for differentiation.

What formulation patents protect metformin extended-release products?

The original Glucophage XR intellectual property centered on controlled-release oral dosage forms and formulation architecture rather than a new chemical entity. The principal composition and extended-release patent estate has aged substantially because the reference product was approved in 2000.

Current commercial risk is therefore less likely to arise from the basic concept of a metformin extended-release tablet and more likely to involve:

• Later-filed formulation patents.
• Specific polymer combinations.
• Coated matrix systems.
• Multiparticulate or modified-release dosage forms.
• Manufacturing processes.
• Fixed-dose combinations.
• Method-of-use claims directed to particular dosing populations.
• Jurisdiction-specific patent rights outside the United States.

A generic applicant must assess current U.S. patent listings in the FDA Orange Book and relevant national registers before filing or launching. The Orange Book identifies listed patents and regulatory exclusivity associated with approved products, but it does not provide a complete freedom-to-operate analysis for every formulation or manufacturing claim.[3]

What is the Orange Book status of metformin hydrochloride extended-release 500 mg?

The U.S. reference product is listed in the Orange Book as a prescription extended-release tablet. The original regulatory and patent exclusivity period has ended, and generic versions are approved. The commercial opportunity is therefore based on cost, supply, quality, and product performance rather than reliance on remaining reference-product exclusivity.[3]

An applicant should distinguish between:

• A patent listed against the reference extended-release product.
• A patent listed against a different strength or dosage form.
• A patent covering a method of use.
• A patent that may be expired, disclaimed, or subject to a terminal disclaimer.
• A patent that could support a Paragraph IV certification.

When does metformin extended-release lose exclusivity?

The original extended-release exclusivity has already ended in the United States. Generic entry has occurred for multiple strengths and manufacturers. The remaining issues are product-specific and jurisdiction-specific.

For a new ANDA, the regulatory pathway may involve:

Certification	Commercial implication
Paragraph I	No relevant patent information listed
Paragraph II	Listed patent has expired
Paragraph III	Applicant waits for patent expiration
Paragraph IV	Applicant asserts that a listed patent is invalid, unenforceable, or not infringed

A Paragraph IV strategy is commercially relevant only if a current, enforceable Orange Book-listed patent creates a meaningful launch barrier. For a mature metformin extended-release product, the greater risk often lies in formulation development, bioequivalence failure, or manufacturing economics rather than in the core reference-product patent estate.

What bioequivalence risks affect metformin extended-release 500 mg?

Modified-release products face more complex bioequivalence requirements than immediate-release tablets. The applicant must generally demonstrate comparable pharmacokinetic performance and dissolution behavior under relevant FDA conditions. Fed and fasting studies can be important because food may affect gastric residence, matrix hydration, and drug release.

Key development risks include:

• Early release that produces a high initial plasma concentration.
• Excessive late release that reduces exposure.
• Food-related changes in absorption.
• Alcohol-induced dose dumping.
• Tablet-to-tablet dissolution variability.
• Failure to match the reference product across multiple dissolution media.
• Scale-up changes in granule density and polymer distribution.
• Excessive tablet hardness that slows hydration.
• Over-lubrication that creates hydrophobic tablet surfaces.

The formulation should be evaluated using a broad dissolution matrix, including multiple pH conditions, agitation rates, and media volumes. A formulation that matches one dissolution condition but diverges under another may create development and regulatory risk.

How can excipients address nitrosamine risk?

Metformin products have been subject to nitrosamine-related recalls and investigations, particularly involving N-nitrosodimethylamine, or NDMA. FDA testing identified contamination in some extended-release metformin products, leading to recalls and increased scrutiny of active pharmaceutical ingredient and finished-product supply chains.[4]

Nitrosamine control should be incorporated into excipient and supplier selection. Relevant controls include:

• Qualification of excipient suppliers and manufacturing sites.
• Assessment of nitrite and nitrate levels.
• Control of secondary and tertiary amines.
• Evaluation of nitrosating conditions during granulation and drying.
• Review of water, solvents, and process aids.
• Testing of metformin hydrochloride API lots.
• Stability monitoring for nitrosamine formation.
• Supplier change-control requirements.

The highest-value commercial proposition may be a metformin extended-release platform with documented low-nitrosamine risk and a controlled supply chain. This can support hospital, retail, and government procurement even where the tablet has no meaningful patent differentiation.

What manufacturing process is best for metformin extended-release tablets?

Wet granulation can improve flow, compressibility, and content uniformity in a high-dose formulation. It also allows more controlled distribution of the release-controlling polymer. The disadvantages are greater process complexity, residual moisture risk, and possible changes in polymer functionality.

Dry granulation or roller compaction can reduce solvent use and simplify processing. It may improve manufacturing economics but can create challenges involving ribbon density, granule size, tablet tensile strength, and dissolution consistency.

Direct compression is attractive for cost and simplicity but may be difficult because of metformin’s high loading and the need to distribute polymer uniformly. It is more suitable where the excipient system provides strong flow and compressibility without excessive tablet size.

Process	Commercial advantage	Main risk
Wet granulation	Strong content uniformity and compressibility	Moisture, scale-up, longer process
Roller compaction	Lower solvent use and continuous-process potential	Density and dissolution variability
Direct compression	Lowest process complexity	Poor flow, segregation, large tablet size
Fluid-bed granulation	Efficient drying and granule engineering	Higher capital and process sensitivity

A contract development and manufacturing organization can create value by offering a validated platform rather than a one-off formulation. The platform can support 500 mg, 750 mg, and 1,000 mg strengths while preserving the same release mechanism.

What commercial opportunities exist for excipient suppliers?

The opportunity is concentrated in performance excipients and formulation-support services rather than commodity fillers.

High-value excipient opportunities

• High-viscosity hypromellose grades optimized for metformin matrices.
• Co-processed excipients that improve flow and compressibility.
• Low-nitrite excipient grades.
• Functionalized polymers with reduced batch-to-batch variability.
• Film-coating systems with moisture protection.
• Lubricant systems that minimize dissolution impact.
• Excipient premixes designed for direct compression.
• Continuous-manufacturing feed systems.
• Analytical packages for dissolution and nitrosamine risk assessment.

Excipient suppliers can differentiate through formulation data, regulatory documentation, supply continuity, and demonstrated performance at commercial scale. A polymer that reduces tablet mass or improves dissolution robustness may generate greater value than a lower-cost conventional excipient.

Opportunities for generic manufacturers

Generic manufacturers can pursue:

• Low-cost high-volume supply.
• Dual sourcing of API and critical polymers.
• Smaller or easier-to-swallow tablets.
• Reduced gastrointestinal intolerance positioning, subject to substantiation.
• Stable dissolution across fed and fasting conditions.
• Lower-nitrosamine supply chains.
• Country-specific strengths and pack sizes.
• Institutional contracts requiring reliable availability.
• Authorized-generic arrangements.
• Fixed-dose combinations with other antidiabetic agents.

Patent-based pricing power is limited. Manufacturing yield, procurement scale, regulatory execution, and supply reliability are more important commercial variables.

How does metformin extended-release compare with competing products?

Product category	Main advantage	Main commercial limitation
Metformin immediate-release	Low cost and simple manufacturing	More frequent dosing and GI intolerance for some patients
Metformin extended-release	Once-daily dosing and modified release	More complex bioequivalence and dissolution requirements
Branded extended-release metformin	Established brand and physician familiarity	Higher price against generic alternatives
Fixed-dose combination	Convenience and adherence potential	More complex development and patent analysis
Other oral antidiabetics	Different mechanisms and clinical positioning	Higher cost or additional safety and reimbursement considerations

Metformin extended-release remains difficult to displace in cost-sensitive markets. Newer antidiabetic classes may grow in value, but they do not eliminate demand for metformin because metformin is inexpensive, widely familiar, and frequently used as background therapy.

What litigation and settlement risks affect the product?

The original product has experienced the normal lifecycle of a mature generic medicine: patent expiry, ANDA approvals, multi-manufacturer competition, and price compression. There is no general biosimilar litigation pathway because metformin is a small-molecule drug.

For a new entrant, litigation exposure may arise from:

• Paragraph IV certification against a later-listed formulation patent.
• Alleged infringement of manufacturing claims.
• Trade-secret disputes involving process parameters.
• Contract disputes over API or excipient supply.
• Antitrust or procurement disputes in high-volume tenders.
• Patent claims directed to fixed-dose combinations.

Settlement agreements may affect launch timing where a valid listed patent remains. Their economic value depends on the patent’s remaining term, market share, number of approved competitors, and whether the settlement permits an authorized generic.

What geographic markets offer the best opportunities?

The United States offers scale but has intense price competition and demanding bioequivalence requirements. Europe has established demand but fragmented national procurement and regulatory procedures. Emerging markets may offer stronger volume growth, although local registration, price controls, and supply-chain requirements vary.

Commercially attractive markets generally have:

• Large diabetes populations.
• High generic substitution.
• Reliable reimbursement.
• Demand for once-daily formulations.
• Local manufacturing incentives.
• Lower penetration of branded modified-release products.
• Clear regulatory pathways for modified-release generics.

A global excipient strategy should account for differences in pharmacopeial standards, permitted colorants, coating requirements, nitrosamine expectations, and stability conditions.

How strong is the patent estate for metformin hydrochloride extended-release 500 mg?

The core patent estate is weak as a barrier to generic entry because the original extended-release technology is mature and multiple generic products are already approved. The remaining defensibility is product-specific.

IP category	Relative strength
Metformin molecule	None for commercial exclusivity
Basic extended-release concept	Low
Specific polymer architecture	Moderate if narrowly claimed and unexpired
Manufacturing process	Moderate, depending on claim scope and evidence
Nitrosamine-control process	Potentially useful but difficult to protect broadly
Fixed-dose combination	Variable, often stronger than standalone metformin
Brand, packaging, and trade dress	Limited pharmaceutical exclusivity

The strongest defensible position is likely to combine a differentiated formulation, documented bioequivalence, reliable manufacturing, and a controlled low-nitrosamine supply chain. A broad excipient patent alone is unlikely to support premium pricing in the United States.

Key Takeaways

• Metformin hydrochloride extended-release 500 mg is a mature generic product with extensive competition.
• The original extended-release patent and exclusivity barriers have largely expired.
• Hypromellose-based hydrophilic matrices are the most practical commercial starting point.
• Polymer grade, concentration, granulation method, and lubrication strongly influence dissolution.
• Nitrosamine control is a major quality and supply-chain opportunity.
• Tablet size, GI tolerability, food-effect performance, and manufacturing yield are commercially relevant differentiators.
• Excipient suppliers can create value through functional polymers, low-nitrite materials, co-processed systems, and regulatory support.
• Generic manufacturers should focus on bioequivalence robustness, cost, supply reliability, and multi-strength platforms.
• Fixed-dose combinations and differentiated manufacturing processes may offer stronger IP positions than standalone metformin.
• The United States is a high-volume but price-compressed market; geographic expansion requires country-specific regulatory and procurement analysis.

FAQs

Is hypromellose suitable for metformin hydrochloride extended-release 500 mg?

Yes. Hypromellose is a widely used hydrophilic matrix polymer for extended-release tablets. Its grade, viscosity, concentration, and particle characteristics must be optimized against the target dissolution profile.

Can metformin extended-release tablets use polyethylene oxide instead of hypromellose?

Yes. Polyethylene oxide can provide matrix swelling and diffusion control. It may offer useful release behavior but requires evaluation of processability, stability, polymer hydration, and scale-up performance.

Does metformin extended-release require an enteric coating?

Usually no. The commercial objective is extended release rather than delayed release through the stomach. An enteric system would require separate performance justification and could complicate bioequivalence.

Is a smaller metformin extended-release tablet commercially feasible?

Yes, but tablet-size reduction must preserve polymer loading, mechanical strength, content uniformity, and release control. High drug loading limits the extent of size reduction.

Can a low-nitrosamine formulation support premium pricing?

It can support procurement differentiation and customer qualification, but premium pricing is difficult in a mature generic market. The commercial benefit is more likely to arise through reduced recall risk, stronger supply continuity, and improved tender competitiveness.

References

1. U.S. Food and Drug Administration. (2000). Glucophage XR: Prescribing information, NDA 021202. FDA.

2. American Diabetes Association Professional Practice Committee. (2024). 9. Pharmacologic approaches to glycemic treatment: Standards of care in diabetes-2024. Diabetes Care, 47(Supplement 1), S158-S178.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (2020). FDA updates and press announcements on NDMA in metformin. FDA.

5. International Council for Harmonisation. (2009). ICH Q8(R2): Pharmaceutical development. ICH.

6. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary, general chapter <711> dissolution. USP.